These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34241920)

  • 1. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis.
    Sheckley H; Malhotra K; Katyal N; Narula N; Govindarajan R
    J Clin Apher; 2021 Oct; 36(5):727-736. PubMed ID: 34241920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
    Yamada C; Teener JW; Davenport RD; Cooling L
    J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.
    Guptill JT; Juel VC; Massey JM; Anderson AC; Chopra M; Yi JS; Esfandiari E; Buchanan T; Smith B; Atherfold P; Jones E; Howard JF
    Autoimmunity; 2016 Nov; 49(7):472-479. PubMed ID: 27684107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
    Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
    Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment.
    Mehrabyan A; Traub RE
    Muscle Nerve; 2024 Apr; 69(4):467-471. PubMed ID: 38284651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
    Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
    Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efgartigimod in refractory autoimmune myasthenia gravis.
    Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
    Muscle Nerve; 2024 Sep; 70(3):325-332. PubMed ID: 38899431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of complications of therapeutic plasma exchange in myasthenia.
    Guptill JT; Oakley D; Kuchibhatla M; Guidon AC; Hobson-Webb LD; Massey JM; Sanders DB; Juel VC
    Muscle Nerve; 2013 Feb; 47(2):170-6. PubMed ID: 23168720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis.
    Yamada C; Pham HP; Wu Y; Cooling L; Kim HC; Morgan S; Schwartz J; Winters JL; Wong EC
    J Clin Apher; 2017 Feb; 32(1):5-11. PubMed ID: 26946363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis crisis.
    Bershad EM; Feen ES; Suarez JI
    South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.
    Cutter G; Xin H; Aban I; Burns TM; Allman PH; Farzaneh-Far R; Duda PW; Kaminski HJ
    Muscle Nerve; 2019 Dec; 60(6):707-715. PubMed ID: 31487038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical features of treatment-refractory myasthenia gravis.
    Rath J; Brunner I; Tomschik M; Zulehner G; Hilger E; Krenn M; Paul A; Cetin H; Zimprich F
    J Neurol; 2020 Apr; 267(4):1004-1011. PubMed ID: 31828474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.
    Fatehi F; Moradi K; Okhovat AA; Shojatalab G; Sedighi B; Boostani R; Sarraf P; Haghi Ashtiani B; Ghasemi M; Moussavi S; Anjidani N; Nafissi S
    Front Neurol; 2021; 12():682622. PubMed ID: 34512504
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcome measures following plasma exchange for MG exacerbation.
    Raja SM; Howard JF; Juel VC; Massey JM; Chopra M; Guptill JT
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2114-2119. PubMed ID: 31560178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.